Foghorn Therapeutics Management
Management criteria checks 3/4
Foghorn Therapeutics' CEO is Adrian H. Gottschalk, appointed in May 2017, has a tenure of 6.92 years. total yearly compensation is $2.50M, comprised of 23.1% salary and 76.9% bonuses, including company stock and options. directly owns 1.2% of the company’s shares, worth $2.64M. The average tenure of the management team and the board of directors is 2.3 years and 6.8 years respectively.
Key information
Adrian H. Gottschalk
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 23.1% |
| CEO tenure | 6.9yrs |
| CEO ownership | 1.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$579k | -US$98m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$5m | US$575k | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$105m |
| Dec 31 2021 | US$4m | US$540k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$85m |
| Mar 31 2021 | n/a | n/a | -US$78m |
| Dec 31 2020 | US$3m | US$479k | -US$69m |
| Sep 30 2020 | n/a | n/a | -US$63m |
| Jun 30 2020 | n/a | n/a | -US$58m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$1m | US$465k | -US$51m |
Compensation vs Market: Adrian H.'s total compensation ($USD2.50M) is above average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Adrian H.'s compensation has been consistent with company performance over the past year.
CEO
Adrian H. Gottschalk (47 yo)
6.9yrs
Tenure
US$2,503,942
Compensation
Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.9yrs | US$2.50m | 1.2% $ 2.6m | |
| Chief Scientific Officer | 2.3yrs | US$1.19m | 0.40% $ 887.3k | |
| Chief Medical Officer | less than a year | US$1.84m | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Financial Officer | no data | no data | no data | |
| VP, Corporate Affairs & Investor Relations | less than a year | no data | no data | |
| Chief Legal Officer | 3.4yrs | US$1.99m | 0% $ 0 | |
| Vice President of Corporate Development | 2.3yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Strategy & Business Operations Officer | no data | no data | 0.18% $ 392.1k |
2.3yrs
Average Tenure
49yo
Average Age
Experienced Management: FHTX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.9yrs | US$2.50m | 1.2% $ 2.6m | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.7yrs | US$157.65k | 0% $ 0 | |
| Independent Director | 6.8yrs | US$159.07k | 0.080% $ 175.8k | |
| Founder & Independent Chairman of the Board | 8.5yrs | US$184.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$153.07k | 0% $ 0 | |
| Independent Director | 7yrs | US$154.57k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$145.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.6yrs | US$252.52k | 8.51% $ 18.7m |
6.8yrs
Average Tenure
64yo
Average Age
Experienced Board: FHTX's board of directors are considered experienced (6.8 years average tenure).